Novel overactive bladder agent found efficacious, well tolerated

October 1, 2011

The investigational selective beta3-adrenoceptor agonist mirabegron effectively improves symptoms of overactive bladder and is very safe and well tolerated.

Key Points

Washington-The investigational selective beta3-adrenoceptor agonist mirabegron effectively improves symptoms of overactive bladder and is very safe and well tolerated, according to results of a North American phase III study presented at the AUA annual meeting in Washington.

Using data from patient diaries, change from baseline to final visit in the mean number of incontinence episodes/24 hours and micturitions/24 hours were analyzed as co-primary efficacy endpoints. The results for both variables showed statistically significant differences favoring both mirabegron, 50 mg, and 100 mg over placebo (incontinence: –1.47 and –1.63 vs. –1.13; micturition frequency: –1.66 and –1.75 vs. –1.05).